Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
SAN CLEMENTE, Calif., June 01, 2017 -- David Steenblock, an osteopathic physician based in San Clemente, CA, is uniquely qualified to address toxicity in the human body through his use of EDTA Chelation Therapy.
Dr. Steenblock uses EDTA (EthyleneDiamineTetraAcetic Acid) Chelation Therapy, a procedure that removes heavy metals from the blood, and consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of patients treated.
“It’s been observed that patients being treated for acute lead intoxification with EDTA with cardiovascular disease, showed improved stress tolerance and less chest pain with physical exertion, “ said Dr. Steenblock.
Dr. Steenblock believes that the benefits of EDTA chelation can improve circulation; reduce cholesterol levels, decrease high blood pressure; and lower insulin requirements in diabetics.
In addition, Dr. Steenblock uses EDTA Chelation Therapy with a combination of hyperbaric oxygen therapy, leading to significant neurologic improvements for stroke patients.
Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases. For more information about Dr. Steenblock’s work in stem cell therapies, visit www.stemcellmd.org.
CONTACT: Irene Doti [email protected]
